Can a New Blood-Based Method (BBAC) Improve Biological Age Calculation?

Biological age becomes more clinically meaningful when the result can be connected to measurable aspects of an individual's physiology.

This is a central feature of BBAC. The method is based on biomarkers familiar from routine clinical practice, while its design allows their individual contributions to the biological-age estimate to remain visible.

Rather than producing only a final biological-age number, BBAC can indicate which biomarker values contributed years to or subtracted years from the estimate. This approach may make biological-age results more transparent and easier to interpret in the context of an individual's health profile.

It may also help bridge an important gap between biological-age research and clinical practice. Complex molecular aging clocks can provide valuable biological information, but specialized testing, cost and limited explainability can restrict their broader clinical application. BBAC explores whether routinely available laboratory measurements can provide a more accessible and interpretable alternative.

Greater interpretability, however, does not by itself establish greater clinical validity. Predictive performance, reproducibility and validation across different populations remain essential.

From a clinical perspective, BBAC addresses an important limitation of many biological-age models: a result may be predictive without being readily explainable at the level of the individual patient.

By retaining the contribution of individual routine biomarkers, BBAC offers a potentially more transparent link between the final biological-age estimate and the physiological measurements from which it is derived.

This distinction is relevant to precision prevention. A biological-age estimate may become more informative when it can be considered alongside the individual measurements contributing to it, rather than interpreted as an isolated number.

Greater explainability, however, should not be mistaken for greater validity. BBAC outperformed PhenoAge in some analyses, but this advantage was not consistent across statistical models, outcomes or populations.

In NHANES, BBAC and PhenoAge performed similarly, while other biological-age measures showed stronger mortality prediction. The findings therefore do not support replacing established biological-age methods with BBAC on the basis of this study alone.

BBAC is also newly published. Independent replication and evaluation in additional populations will be important before its broader clinical value can be established.

For the development of clinically meaningful Biological Age Calculators, BBAC introduces an important principle: performance should be considered alongside transparency. A useful biological-age estimate should not only be associated with meaningful health outcomes, but should also allow clinicians and patients to understand what contributed to the result.